Compile Data Set for Download or QSAR
Report error Found 491 Enz. Inhib. hit(s) with all data for entry = 8731
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415317(US10428044, Example 426 | Preparation of 3-{[2-(hy...)
Affinity DataIC50: 2.58nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415374(US10428044, Example 487 | Preparation of 3-{[5-flu...)
Affinity DataIC50: 3.35nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415373(US10428044, Example 486 | Preparation of 3-{[3-flu...)
Affinity DataIC50: 3.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415303(US10428044, Example 410 | Intermediate 1-2-69)
Affinity DataIC50: 3.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415283(US10428044, Example 390 | Preparation of 1-(1-meth...)
Affinity DataIC50: 3.96nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414909(US10428044, Example 7 | US10428044, Example 18 | U...)
Affinity DataIC50: 4.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415365(US10428044, Example 478 | Preparation of 1-benzyl-...)
Affinity DataIC50: 4.23nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415336(US10428044, Example 449 | Preparation of 1-benzyl-...)
Affinity DataIC50: 4.38nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415357(US10428044, Example 470 | Preparation of N-{4-[4&#...)
Affinity DataIC50: 4.49nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415284(US10428044, Example 391 | Preparation of 1-{4-[6,6...)
Affinity DataIC50: 4.52nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415331(US10428044, Example 444 | 2-{[(2-aminopyridin-4-yl...)
Affinity DataIC50: 4.61nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415353(US10428044, Example 466 | Preparation of rel-(R,S)...)
Affinity DataIC50: 5.03nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415359(US10428044, Example 472 | Preparation of 1-tert-bu...)
Affinity DataIC50: 5.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415330(US10428044, Example 443 | Preparation of 6-(chloro...)
Affinity DataIC50: 5.05nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414909(US10428044, Example 7 | US10428044, Example 18 | U...)
Affinity DataIC50: 5.09nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415366(US10428044, Example 479 | Preparation of N-{4-[6,6...)
Affinity DataIC50: 5.09nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415379(US10428044, Example 492 | Preparation of N-{4-[4-o...)
Affinity DataIC50: 5.28nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414932(Preparation of 3-[(3,5-difluorophenyl)amino]-6,6-d...)
Affinity DataIC50: 5.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414909(US10428044, Example 7 | US10428044, Example 18 | U...)
Affinity DataIC50: 5.57nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414931(Preparation of 2-(3-fluoropyridin-4-yl)-6,6-dimeth...)
Affinity DataIC50: 5.69nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415372(US10428044, Example 485 | Preparation of 3-{[4-flu...)
Affinity DataIC50: 5.84nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414929(Preparation of 6-ethyl-3-(phenylamino)-2-(pyridin-...)
Affinity DataIC50: 5.93nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415391(US10428044, Example 504 | Preparation of N-{4-[6,6...)
Affinity DataIC50: 6.14nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414930(Preparation of 6-(2-methylpropyl)-3-(phenylamino)-...)
Affinity DataIC50: 6.17nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415244(US10428044, Example 351 | Preparation of 2-[(1-met...)
Affinity DataIC50: 6.22nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415337(US10428044, Example 450 | Preparation of 1-(4-meth...)
Affinity DataIC50: 6.24nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414900(6,6-dimethyl-3-(phenylamino)-2-(pyridin-4- yl)-1,5...)
Affinity DataIC50: 6.25nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415367(US10428044, Example 480 | Preparation of N-{4-[6,6...)
Affinity DataIC50: 6.30nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415152(US10428044, Example 254 | Preparation of (S,R) N-{...)
Affinity DataIC50: 6.34nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415108(Preparation of 2′-(3-fluoropyridin-4-yl)-3&#...)
Affinity DataIC50: 6.39nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415301(US10428044, Example 408 | Intermediate 1-2-68)
Affinity DataIC50: 6.42nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415248(US10428044, Example 355 | Preparation of 2-[(5-met...)
Affinity DataIC50: 6.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415383(US10428044, Example 496 | Preparation of 2-[(4-met...)
Affinity DataIC50: 6.46nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415243(US10428044, Example 350 | Preparation of 2-[(3-met...)
Affinity DataIC50: 6.53nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM414915(Preparation of 3′-(phenylamino)-2′-(py...)
Affinity DataIC50: 6.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415247(US10428044, Example 354 | Preparation of 2-[(5-met...)
Affinity DataIC50: 6.57nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415364(US10428044, Example 477 | Preparation of N-{4-[6,6...)
Affinity DataIC50: 6.62nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415167(US10428044, Example 272 | Preparation of N-{4-[6,6...)
Affinity DataIC50: 6.63nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415245(US10428044, Example 352 | Preparation of 2-(furan-...)
Affinity DataIC50: 6.68nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415304(US10428044, Example 411 | Intermediate 1-2-70)
Affinity DataIC50: 6.86nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415348(US10428044, Example 461 | Preparation of N-{4-[6-(...)
Affinity DataIC50: 6.88nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415329(US10428044, Example 442 | Intermediate 1-1-32)
Affinity DataIC50: 6.97nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415235(US10428044, Example 342 | Preparation of 2-[(4-met...)
Affinity DataIC50: 7.12nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415352(US10428044, Example 465 | Preparation of N-{4-[6,6...)
Affinity DataIC50: 7.19nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415233(US10428044, Example 340 | Preparation of 2-(benzyl...)
Affinity DataIC50: 7.25nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415107(Intermediate 1-2-37 | US10428044, Example 207)
Affinity DataIC50: 7.32nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415226(US10428044, Example 333 | Preparation of 2-butoxy-...)
Affinity DataIC50: 7.33nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415341(US10428044, Example 454 | Preparation of 1-methyl-...)
Affinity DataIC50: 7.33nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415149(US10428044, Example 249 | Preparation of rel-(R,S/...)
Affinity DataIC50: 7.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM415166(US10428044, Example 271 | Preparation of N-{4-[4-o...)
Affinity DataIC50: 7.64nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 491 total ) | Next | Last >>
Jump to: